Forward Science Receives FDA Clearance for Orapeutic

Forward Science received FDA Clearance for Orapeutic, a non-opioid oral pain relief gel. The company’s flagship product, OralID, received FDA Clearance in March of 2013 and has since revolutionized the way clinicians screen for early stage oral cancer. In 2016 the company launched SalivaMAX in efforts to provide patients with a clinically proven option to mitigate the effects of xerostomia and mucositis. Orapeutic, the company’s third FDA cleared product, has been developed to fight the current opioid epidemic that the healthcare industry is facing today.

"We are proud of our previously released products and their impact on the healthcare industry, but our R&D team is always striving to develop products that meet market demands," said Forward Science co-founder and Chief Technology Officer Brian Pikkula, PhD. "With the success of our previous product launches, we have become the industry’s leader of innovative solutions in oral healthcare. We are thrilled to receive FDA clearance for Orapeutic and are looking forward to hearing from clinicians as to how this product impacts their patients."

Dentists and oral surgeons are by far the majority of prescribers for opioids to people ages 10-19. With the recent concerns surrounding opioid prescription in the dental industry, Forward Science has been working on a non-drug option to manage oral pain, and Orapeutic will do just that.

Forward Science expects to launch Orapeutic in early 2020 to complement their current therapeutic options for healthcare providers.

Orapeutic Oral Pain Gel manages the pain of oral wounds, mouth sores, injuries and ulcers of the oral mucosa. It adheres to the oral tissue and forms a protective barrier between the wound and further prevents irritation and contamination. Orapeutic Oral Pain Gel also maintains a moist wound environment.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.